Healius Limited Reports Strong Revenue Growth Amid Strategic Changes

Healius Limited ( (AU:HLS) ) just unveiled an update.

Healius Limited reported a significant revenue increase of 10% for the first half of FY25, reaching $933.9 million, with underlying EBITDA and EBIT also showing positive growth. Notably, the pathology division saw a 7% revenue rise due to market expansion and better center performance, although cost inflation and labor expenses remain challenges. The imaging segment, Lumus Imaging, experienced a 13.3% revenue boost, driven by organic volume growth and strategic initiatives, and is set for sale to Affinity Equity Partners. Healius plans to return proceeds from this sale to shareholders via a special dividend, post debt refinancing. However, the company is actively opposing government cuts to certain pathology tests, which could impact future revenues.

More about Healius Limited

Healius Limited is a prominent player in the healthcare sector, offering services such as pathology and medical imaging. It focuses on delivering comprehensive healthcare solutions with a keen emphasis on diagnostic services, targeting both general practitioners and specialist markets.

YTD Price Performance: 4.88%

Average Trading Volume: 2,065

Technical Sentiment Consensus Rating: Strong Buy

Current Market Cap: €642.2M

Learn more about HLS stock on TipRanks’ Stock Analysis page.